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Technological developments have allowed improvements in radiotherapy delivery, with higher precision and
better sparing of normal tissue. For many years, it has been well known that ionizing radiation has not only local
action but also systemic effects by triggering many molecular signaling pathways. There is still a lack of
knowledge of this issue. This review focuses on the current literature about the effects of ionizing radiation
on the immune system, either suppressing or stimulating the host reactions against the tumor, and the factors
that interact with these responses, such as the radiation dose and dose / fraction effects in the tumor
microenvironment and vasculature. In addition, some implications of these effects in cancer treatment, mainly
in combined strategies, are addressed from the perspective of their interactions with the more advanced
technology currently available, such as heavy ion therapy and nanotechnology.
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’ INTRODUCTION
Radiotherapy is one of the cornerstone treatment mod-
alities for cancer. It is also the most commonly used cancer
treatment strategy, with approximately 60% of patients with
solid tumors receiving curative or palliative irradiation as
part of their treatment (1).
High precision techniques are currently available, making
treatment delivery more safe and effective, while sparing
adjacent normal tissue (2).
Radiation-induced cell death is modulated by several
factors related to the molecular physicochemical effects that
induce cellular stress. Depending on the dose and irradiation
schedules used, cellular senescence or death will occur as a
result of the disequilibrium caused by the stress (3).
The tumor microenvironment, especially the degree of
oxygenation, has also long been known to influence the
response to radiation. This has broadened the studies on
radiobiology that currently include the effects of radiation on
tumor vasculature, fibroblasts and immune cells (4).
There is growing interest in research on immunotherapies
based on the critical role of the immune system in cancer
development and dissemination (5). The anticancer immune
response may also be activated by ionizing radiation, and a
combination of different treatment strategies is promising in
this field (3,6).
The objective of this manuscript was to provide a brief
update about the role of radiotherapy in cell death and
the activation of the antitumor immune system from the
perspective of clinical applications in oncologic treatment.
Radiation-induced cell death
The effect of radiation on biological material is due to the
absorption of energy from X-rays or gamma rays, or from
charged particles within the atoms that may be ionized or
excited, initiating a chain of actions that lead to a final bio-
logical effect (6). Within tumor cells, DNA is the main target of
radiation. The so-called lethal effect is caused by a direct
action of radiation causing DNA damage. Radiation may also
act indirectly by interacting with other atoms and molecules in
the cell, mainly water, called ‘‘radiolysis of water’’, to produce
free radicals that are able to trigger chemical reactions with
different targets. This indirect action produces sublethal
or potentially lethal damage and may lead to cell death (7).
The different cellular mechanisms triggered after exposure to
ionizing radiation cell death may be expressed in different
ways. Galluzzi et al. (7), in 2007, proposed three main moda-
lities of cell death that may be ordered according to morpho-
logical, biochemical and enzymatic processes as follows:
apoptosis – type I, autophagic cell death – type II, and necro-
sis or necroptosis – type III.
Apoptosis
Apoptosis also called programed cell death is characterized
by classical morphological alterations such as cellular shrink-
age, chromatin condensation (pyknosis), nuclear fragmen-
tation (karyorhexis), plasma membrane blebbing, and the
formation of apoptotic bodies that are engulfed by neighbor-
ing phagocytes very quickly without inducing inflammatoryDOI: 10.6061/clinics/2018/e557s
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processes (8). Apoptosis is the most important form of
radiation-induced cell death, and the following two distinct
signaling pathways may be involved in its activation: the
intrinsic and the extrinsic pathways, driven by intracellular
signals such as DNA damage and metabolic alterations and
extracellular signals such as death ligands, respectively (3).
A cascade of caspases is activated in both pathways. These
cascades act in both apoptosis mechanisms and other cellular
processes that are independent of cell death modalities. (9).
Autophagic cell death
Autophagic cell death is a concept that should be
differentiated from autophagy. Autophagy is a regulatory
mechanism that acts to maintain cellular homeostasis and to
protect genomic integrity through a lysosomal pathway. The
lysosomes prevent the accumulation of aggregated and mis-
folded proteins as well as the action of damaged organelles
and helps in the maintenance of homeostasis (10). Many
anticancer therapies, including chemotherapy and radio-
therapy, may induce autophagy in tumor cells. However,
depending on the cellular context at the time and the type of
treatment, the treatment response may inhibit or favor tumor
progression in an autophagy-mediated manner by autop-
hagy-related (ATG) proteins (11,12). In addition, at least
some portion of radiation-induced apoptosis is dependent on
the autophagic process in some tested cell lines, and some
reports demonstrated that cell death after irradiation could
be decreased by the inhibition of autophagy (13).
Autophagic cell death, on the other hand, is defined as
a distinct process that occurs after the induction of cell
autophagy (14). This may be explained by the finding that
inhibitors of autophagy function and/or genetic inactivation
of autophagic modulators may block autophagic cell death
(15). However, in some situations, it can occur in another
way. In a recent publication, the protein ATG5, for example,
was implicated in the induction of autophagic cell death
after irradiation (13), a process rendered distinct from the
induction of autophagy by the inhibition of the mTOR and
kinase AKT pathway (12).
Thus, during cancer treatment, autophagy can contribute
to the regulation of the fate of cancer cells (3).
Necrosis or necroptosis
Necrosis is another form of cell death characterized by
organelle swelling, plasma membrane rupture, and cell lysis
with loss of intracellular content (16). This form of cell death
leads to the release of intracellular components and causes an
intense inflammatory response not observed in other forms.
The term ‘‘necroptosis’’ was proposed to indicate a regu-
lated (not accidental) process of necrosis. Necroptosis may be
defined as a type of cell death that can be avoided by inhibi-
ting kinase RIP1, a cell death mediator (either through genetic
or pharmacological methods) (17). These mediators may repre-
sent a way to discriminate programmed from uncontrolled
forms of necrosis (17). Therefore, strong evidence suggests
that necrosis is not an uncontrolled process but may be regu-
lated by a number of signal transduction pathways and
catabolic mechanisms, as has been described in other forms
of cell death (17,18).
Radiation-induced death is particular to each cell tissue
and tumor, and the prevalence of the death of some types of
cells over other cells can be changed by the dose. Radia-
tion in low doses generally eliminates cancer cells through
apoptosis, while high doses can lead to necrosis in other
cancer cells, such as osteosarcoma cells (19).
Atypical radiation-induced cell death modalities
Atypical cell death modalities are defined as those that do
not or that only partially exhibit the morphological features,
biochemical alterations and enzymatic activities described.
They are less studied and are called mitotic catastrophe and
senescence (3).
Mitotic catastrophe is also a response that can be induced
after irradiation in cells. It occurs in cells with impaired p53.
These cells have problems in the repair process because they
are not able to properly activate the cell cycle checkpoints to
initiate cell cycle arrest and DNA repair. The DNA lesion
promoted by irradiation, deficient cell cycle checkpoints
and repair, and hyperamplification of centrosomes contri-
bute to mitotic catastrophe. Apoptosis and mitotic cata-
strophe are among the most frequent forms of cell death due
to radiation (20).
The cells have an aberrant nuclear morphology, often
resulting in aneuploid and polyploid cell descendants that
almost always die (21,22). Cancer cells containing unre-
paired, defective DNA enter prematurely into mitosis and
experience mitotic catastrophe (22). Anti-proliferative actions
can be utilized to stop proliferation of cells with defective
mitosis. When this protective mechanism is impaired,
unrestricted growth of defective cells, such as tumor cells,
may occur, facilitating tumor development (21,23).
Senescence is defined as a widespread and permanent cell
cycle arrest after the proliferative capacity of the cells is
exhausted. This process is considered an antitumor barrier
that prevents cancer cell proliferation (3). However, senescent
cells are still viable and metabolically active (17, 21). They
can secrete many pro-inflammatory cytokines, chemokines,
growth factors, and proteases that collectively are known as
the senescence-associated secretory phenotype (SASP). These
can have positive effects or not on cellular proliferation.
Therefore, while senescence represents a cell-autonomous
tumor suppressor mechanism, radiation-induced senescence
could impact the surrounding cells and favor tumor survival
and growth (3).
Nontargeted effects of radiation
Allied to these primary effects of radiation on cell death,
mostly promoted by DNA lesions, other secondary effects
can also be observed. The main effect seems to be due to
the activation of the immune system via the induction of
immunogenic cell death by ionizing radiation. Radiation is
able to modify tumor phenotypes and the tumor micro-
environment as well. Anti-tumor responses may also be
mediated by these nontargeted effects in a specific and
systemic manner and have the ability to target both relapsing
tumor cells and distant metastases (21,24-26).
Cancer and immune system
Tumors develop in a microenvironment composed of cells
of the immune system. The immune system can modulate
either tumor suppression or progression. Cancer immunoe-
diting comprises the dual host-protective and tumor-promot-
ing actions of immunity (27,28). Cancer immunoediting is
a dynamic process composed of the following three phases:
elimination (i.e., cancer immunosurveillance), equilibrium,
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and escape. This process is also known as the three ‘‘Es’’ of
cancer immunoediting (29).
In the first phase, elimination, cells and molecules of the
innate (natural killer cells – NK, and macrophages) and
adaptive (dendritic cells – DC, CD8+ and CD4+ T lympho-
cytes) immunity, which comprise the cancer immunosurveil-
lance network, interact with the highly immunogenic tumor
cells that are present at the beginning of the carcinogenic
process. These immune cells may eradicate the growing
tumor and protect the host from tumor formation. However,
due to genetic instability, cells that are more resistant to the
immune attack may emerge but remain under the constant
control of the immune system, which is the equilibrium
phase. Maintained chronically or immunologically in this
immune ‘‘editor’’ environment, they may produce new
populations of tumor variants. These variants may occasion-
ally escape the immune system by different mechanisms and
become clinically detectable in the escape phase. At that
point, not only do the tumor cells present fewer antigens
but they also promote the recruitment of immunosuppres-
sive cells that inhibit the local effector cells. Among them,
T regulator (Treg) lymphocytes, myeloid-derived suppressor
cells (MDSCs), the secretion of indoleamine 2,3-dioxygenase
(IDO) and cytokines such as interleukine-10 (IL-10) are the
most important in the establishment of a highly immuno-
suppressive environment. In this way, the tumor escapes
from immunosurveillance and becomes clinically detectable
(29,30).
Ionizing radiation and the immune system
The effects of ionizing radiation are seen not only in the
tumor cells but also in the tumor microenvironment. In
general, lymphocytes (T cells, B cells and NK) are among the
most radiosensitive cells, followed by monocytes, macro-
phages and antigen-presenting cells (APCs), specifically
dendritic cells (DC), which have a higher radioresistance
(31-33). Ionizing radiation also has an effect on the vascular
endothelium, with an increase in the production of mole-
cules involved in cellular adhesion, which facilitates the
recruitment of antitumor T cells against the corresponding
sites (34).
After irradiation, dead and stressed cells release a variety
of substances that gives ionizing radiation either immuno-
suppressive or immune stimulating properties. There is still a
lack of information on the role and functionality of immune
cells after irradiation. Nevertheless, a number of experi-
mental studies have clarified some aspects of the immune
response after exposure to radiation.
Radiation induces distinct tumor cell death forms and,
consequently, the release of pro-inflammatory cytokines,
chemokines, tumor antigens, and other danger signals.
Through this mechanism, radiation may enhance tumor
immunogenicity. Radiation may promote a large amount
of tumoral neoantigens that are then presented to the
T lymphocytes. Therefore, radiation carries the potential to
initiate the adaptive and innate immune responses, resulting
in systemic antitumorigenic effects inside and outside of the
irradiation field (35).
The observed regression of metastases or tumors outside
the irradiation field is called the abscopal effect, and its
relationship with immune events has been known since 1969
(36). The abscopal effect is partially mediated by the immune
system, and T cells are the cells elected to mediate distant
tumor immune inhibition induced by radiation (37). More
recently, this radiation-induced cell death that causes an immune
reaction has also been called ‘‘immunogenic death’’ (38).
After cell death, pro-inflammatory mediators are released.
They are called damage-associated molecular patterns
(DAMPs). Among them, we have reactive oxygen (ROS)
and nitrogen species, cytotoxic cytokines tumor growth
factor b-1 (TGb-1), tumor necrosis factor-alpha (TNF-a),
a number of interleukins, heat shock proteins (HSPs), high
mobility group box 1 molecules (HMGB1), and nucleotides
or uric acid are capable of activating the innate or adaptive
immune system (39). These DAMPs are recognized by the
Toll-like receptors (TLR) expressed on the surface of the DCs
and are responsible for their activation and maturation (40).
Tumor infiltrating DCs are associated with either good
or poor prognosis in different cancer types. Although they
seem to be quite radioresistant, radiation may cause a fun-
ctional impairment of DCs, possibly leading to a change
in the DC-mediated balance between T-cell activation and
tolerance (41).
Adenosine-5-triphosphate (ATP) is another inflammatory
molecule associated with immunological cell death. ATP
binds to the DC receptors and can stimulate the release of
interleukin-1b (IL-1b), which can promote T cell priming.
Moreover, ATP released from tumor cells also modulates the
immunosuppressive properties of myeloid-derived suppres-
sor cells (MDSCs) and contributes to tumor growth (42).
The MDSCs together with other cells such as tumor-
infiltrating macrophages or tumor-associated macrophages
(TAMs) can contribute to tumor growth and inhibit anti-
tumor immunity (3). This paradoxical immunosuppressive
effect of radiation is mainly due to the inactivation of NK
lymphocytes, with the recruitment of MDSCs and Treg
lymphocytes, secretion of TGF-b and the modification of the
macrophage phenotype (43).
A summary of these paradoxical immune responses after
irradiation is represented in Figure 1. Understanding the role
of these cells in the anticancer immune response is important
for the development of anticancer therapies. Cell death
causes an intense inflammatory response due to the release
of intracellular components.
Effects of ionizing radiation on the tumor
microenvironment (TME)
Currently, we recognize that ionizing radiation effects not
only affect cancer cell and cancer cell death but also the
complex biological interactions between tumors and stroma
in which they grow, known as the tumor microenvironment
(TME). It is becoming increasingly evident that responses
that are triggered within TME may be critical in determining
the success or failure of therapy (44).
Tumor vasculature
Endothelial cells and the tumor vasculature are possibly
the best studied components involved in the effect of radi-
ation on the TME. Radiation induces endothelial cell dys-
function, which is characterized by increased permeability,
detachment from the underlying basement membrane and
apoptosis (45). This effect is observed especially with high
single-fraction doses (8–16 Gy) that induce endothelial cell
apoptosis by the upregulation of acid sphingomyelinase
(ASMase) (45). Thus, endothelial cell dysfunction and
apoptosis caused by radiation contribute to postirradiation
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inflammation and fibrosis. Within vessels, irradiation also
generates a pro-thrombotic state characterized by platelet
aggregation, microthrombus formation and increased adhe-
sion of inflammatory cells to endothelial cells with subse-
quent diapedesis into the perivascular space (46).
Structurally, irradiation of the vasculature can cause the
destruction of blood vessels. The main structure affected is
microvasculature (45,47), and the effect is dose-dependent.
In addition to the total dose and fraction size, other
important points involved are the tumor type, location
and stage. All these factors are related to the effect of
radiation on the vasculature (45,48). Tumor hypoxia, which
could be a factor for tumor radioresistance, can be poten-
tiated by the vascular damage caused by radiation. However,
it generates an increased production of cytokines/chemo-
kines that induces immune cell recruitment and triggers
immune responses (45).
Effects of radiation dose and fractionation on
immune activation
The effects of radiation on the tumor microenvironment
and immune system may be modified by the radiation dose
and the dose delivery methods used. The model of tumor
control by radiation is mainly based on cell damage due to
direct and indirect effects. This model was developed with
the conventional standard dose fractionation of 2 Gy per
fraction (49). However, the effects of radiotherapy on the
TME and on the antitumoral immune response described in
preclinical studies has led to the concept of an existing
immunogenic cell death (ICD) and immune-mediated tumor
rejection (50,51).
To date, a variety of hypotheses about the specific impact
of different dose/fractionation regimens on the anti-tumoral
response are under investigation. In preclinical studies, the
use of hypofractionated high doses rather than high single
dose schedules showed the best results regarding the pro-
immunogenic effect of radiation. (50,52,53).
In addition, larger doses should have more pro-immuno-
genic effects regarding the induction of ICD in in vitro studies
(54). However, the relationship of the immune response with
dose and fractionation may be more complex, as suggested
by in vivo studies (55,56). The ability of radiotherapy to
trigger anti-tumor T cells is influenced by the pre-existing
TME and by the effects of radiotherapy on the TME (45).
Currently, a consensus about the optimal dose schedule to
stimulate the immune system has not yet been achieved with
preclinical data that have been published. The use of single
Figure 1 - The effects of ionizing radiation effects on the immune system. Either stimulation or suppression of the immune
system occurs. Stressed cells may simply undergo anti-inflammatory clearance resulting in non-immunogenic cell death or trigger
inflammatory signaling that will release damage-associated molecular patterns (DAMPs) with the activation of dendritic cells that
initiate cytotoxic T-cell responses against tumor cells. On the other hand, inactivation of these cells (DCs and cytotoxic T-cells) with the
recruitment of MDSCs and T regulator lymphocytes and the secretion of TGF-b leads to the modification of the macrophage phenotype
from a pro-inflammatory type M1 to an immunosuppressive type M2 that may allow tumor growth and progression. [Adapted from
Derer et al., 2015 (44) and Bockel et al., 2017 (93)].
Abbreviations: TGF-b, tumor growth factor-b; IL, interleukin; RT, radiotherapy; HSP, heat shock proteins; HMGB1, high mobility group
box 1 molecules; ATP, adenosine-5-triphosphate; TNF, tumor necrosis factor; NOS, nitrogen reactive species; DC, dentritic cells; NK,
natural killer; MDSC, myeloid derived suppressor cells; Treg, T regulator lymphocyte; TGF-b, tumor growth factor-b; TAM, tumor-
associated macrophages.
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large doses (e.g., 30 Gy), as well as the 2 Gy standard dose,
or even the classic hypofractionated doses of 6 or 8 Gy
delivered daily on consecutive days have all been described
as being effective (55-57).
Therefore, the radiation and immunotherapy partnership
is completely dependent on the radiation dose and fraction
involved.
Association of radiotherapy with immunotherapies
Many immunotherapies were tested in combination with
radiotherapy in preclinical studies and are now under
investigation in the clinical setting (52). Among them, several
immunological manipulation treatments have been used,
including immune checkpoint blockade, adaptive T cell
transfer, cytokine therapy, dendritic cell and peptide vac-
cines, and monoclonal antibodies.
The induction of anti-tumor immunity seems to be regu-
lated step by step by positive and negative signals. Immuno-
therapies that have been currently approved and those in
development act at one or multiple steps of this process.
Radiotherapy seems to potentially accentuate each step,
including the uptake of tumor antigens by dendritic cells and
their activation, as well as migration of the activated effector
T cells back to the tumor. Therefore, radiotherapy enhances
and complements the action of many different immunother-
apy agents, and its synergistic use is the goal of many
exploratory studies (52,57-59).
Radiotherapy techniques and perspectives
With respect to the tolerance dose of normal tissue and
side effects, conventional regimens of radiation treatments
deliver an effective dose of 40 to 70 Gy to achieve tumor
control, depending on the tumor type, in daily doses of 1.8
to 2 Gy/day, delivered over several weeks. The advances
in radiotherapy machines and planning systems have
allowed the delivery of highly accurate treatments with
high precision. Currently, it is possible to deliver higher
doses per fraction with better sparing of the adjacent
normal tissue. Techniques such as intensity-modulated
radiation therapy (IMRT), image-guided radiation therapy
(IGRT), stereotactic radiosurgery (SRS), and stereotactic
body radiation therapy (SBRT or stereotactic ablative
radiotherapy - SABR) have transformed the delivery of
radiotherapy, and the trend is the increasing use of
hypofractionated schedules. With stereotactic techniques,
single doses as high as 20 to 24 Gy or highly hypofractio-
nated schemes such as 54 to 60 Gy in three fractions can be
safely delivered in small targets.
Published papers have suggested that SBRT regimens can
promote an immune response, mediating anti-tumorigenic
effects (60). The generation of an effect in the TME that can
initiate an immunological response may support this theory
(61). Two aspects will be important in the elucidation of this
effect are evaluation of immune cell response to high-dose
SBRT regimens and cancer stem cell clearance to exclude any
effect of endothelial damage (62).
Cancer stem cells have been implicated in the radio-
resistant characteristics of tumors. This cell type may be
responsible for tumor recurrence following fractionated
radiotherapy (62,63). Cancer stem cells increase the activa-
tion of the AKT/mTOR pathway, which regulates cell
proliferation and survival (62). Therefore, the efficiency of
SBRT with a high dose can be responsible for the increase
in the number of cell targets damaged and for the ablation
of cancer stem cells, which is a focus of radioresistance
(61,62).
Changes in the TME could also have a marked impact on
the response of tumor cells to treatment (63,64). Not only
may the effects on endothelial cells and tumor vasculature
contribute to tumor growth or control, but other stroma cell
populations may also be involved. The mechanisms respon-
sible for the radiation effect and tumor relapse following
high-dose radiotherapy have been explored in more recent
experiments (64,65).
Combination of particle radiotherapy
with immunotherapy
Photon-based radiation (i.e., gamma rays and X-rays) and
small particles, such as electron beams, have been used to
treat all types of cancer and some nonmalignant disorders.
Heavy particle radiotherapy (i.e., protons and carbon ions)
has specific physical properties and biological effectiveness
that are very attractive in the clinic and are now becoming a
more popular treatment modality (65).
Particle beams may be as effective as, or more advanta-
geous than, photon beams in immune combination therapy.
The same relative biological effective (RBE) dose induces
different biological responses when particles are used com-
pared to photon beams (3 times more efficient). Another
interesting point observed in several studies was the effect of
particle beams on the tumor metastatic potential. In some
cases, treatment with X-rays increased the metastatic poten-
tial of a tumor, while carbon ion beams effectively sup-
pressed it (66).
Sublethal doses delivered with carbon ion beams inhibited
in vitro angiogenesis (67) and the expression of angiogenesis
mediators (68,69). In immune-competent mouse models,
lung metastasis was significantly suppressed by carbon ion
irradiation (66,70).
When heavy particles are used compared to conventional
photons, there is an inverted depth-dose profile, with a low
entrance dose, followed by a peak dose at a certain depth
(Bragg peak), with a sharp fall-off afterwards that allows
for a more precise dose delivery (66,71). Recent studies
also suggest another advantage of both protons and carbon
ions because they have unique biological properties when
compared with photons (66,71,72). They have the character-
istic of high-linear energy transfer (LET) of these particles
(66,72,73). Considering these special characteristics (physical
and biological), particle therapy could have important and
different effects on immune alterations. The response caused
would define the type and magnitude of local and systemic
(abscopal) immune effects (74).
A few preclinical in vitro and in vivo studies investigated
the effects of particle radiotherapy on the modification of
tumor cell phenotypes and whether this would increase their
sensitivity to immune surveillance. Proton irradiation mod-
ulates several processes critical in tumor growth and pro-
gression, including angiogenesis and immunogenicity.
Decreased levels of factors that may influence the tumor
response to radiation and the host immune response, such as
vascular endothelial growth factor (VEGF), IL-6, IL-8, and
hypoxia-inducible factor 1-alpha (HIF 1-a), were observed in
lung carcinoma cells exposed to proton irradiation (74,75).
Likewise, sublethal doses of proton or photon irradiation
induced a similar increase in the levels of surface molecules
involved in T-cell recognition as well as the translocation of
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calreticulin to the tumor cell surface (76). These changes in
calreticulin are critical for increased sensitivity to T cell killing
and render tumor cells more sensitive to T cell-mediated cell
death. In a human in vitro model, the levels of HMGB1 in
different human cancer cell lines were increased by carbon ion
radiation. However, when the dose was changed to the levels
used in the clinic, this effect was comparable to that produced
by irradiation with X-rays (77).
Carbon ion exposure also induces antitumor immunity
and abscopal effects in some cases, as described in preclinical
in vivo studies. When compared with photon irradiation, the
number of distant lung metastases was reduced, and higher
expression levels of membrane-associated immunogenic
molecules were observed in carcinoma models in immuno-
competent mice (78). In both studies, immunocompetent
mice received bone marrow DCs and irradiation. In addition
to the potential of carbon ion exposure alone to activate DCs,
the combined treatment showed a synergistic effect. How-
ever, the combination of DC immunotherapy with photon
radiation was not able to induce the same effects. These
studies suggest that carbon ion therapy with the same dose
might generate a stronger activation of the immune system
than conventional photon radiotherapy (79,80).
Perspectives in treatment with new technologies
In recent years, nanotechnology has emerged as a new
scientific point of interest. It is another tool in medical
treatments that is emerging as a promising therapeutic plane.
There are significant numbers of clinical benefits reported.
The nanomaterials present wide potential for medical use,
including tissue engineering protein detection and drug
and/or gene delivery. The inclusion of nanoparticles (NPs)
into both diagnostic and radiation therapy settings, empha-
sizing their use as potential agents in the combination of
diagnosis and therapeutics, may be promising (81,82).
Nanotechnology and radiation therapy
Nanotechnology may be incorporated into ionizing radia-
tion treatments (82). Radiosensitizing NPs, for example, have
the potential to increase the radiation dose delivered to
tumor cells while sparing adjacent normal tissue, optimizing
the therapeutic ratio in in vivo studies (83). Elements with a
high atomic number (Z) have a strong photoelectric absor-
ption when irradiated with X-rays. High-Z NPs (particularly
gold NPs) were initially considered radiation contrast agents.
In addition, a potential benefit of the combination of these
NPs with low energy (kV) X-rays was observed. The associa-
tion produces a radiation dose increase, with a potential
increase in cell death. Likewise, successful radiosensitization
was observed in early in vivo work related to this issue (84).
However, it was also observed that the increase in the phy-
sical dose does not fully explain the observed large increase
in radiosensitization (85).
These findings demonstrate that the factors that impact NP
radiosensitization still need to be better understood (82).
It seems that, together with their impact on the physical
dose distribution, NPs also induce some degree of biological
sensitization of tumor cells. Physically, high-Z NPs promote
an increase in total dose absorption and the release of a large
number of lower energy X-rays and Auger electrons due to
the photoelectric effect. The energy released by these parti-
cles is deposited very nearby, resulting in highly localized
damage. This is responsible for an increased biologic effect
and results in higher damage (82). Some NP preparations may
also produce additional biological effects, such as mitochon-
drial stress or the production of reactive oxygen species, that
may also enhance the effectiveness of radiation (82).
The development of the targeted uptake of NPs may help
to increase the dose to the tumor without changing the dose
to the adjacent normal tissue. This effect is relevant regarding
SBRT treatments, in which the highly hypofractionated
treatment schedule requires a high degree of precision to
avoid any geometric mistakes, with impacts on tumor con-
trol and toxicity. Therefore, the combination of NPs with
SBRT not only has the biological potential of increasing ICD
but also has improved the therapeutic ratio (82,83).
Nanoparticles have also been explored as vectors for
radiation protection agents in radiotherapy (83,86).
Reduction of bone marrow toxicity during external beam
radiotherapy was observed in mice after the intravenous
administration of melanin-coated NPs, with an influence on
tumor control (87).
Clinical implications / on-going trials
The potential benefits of the combination of radiotherapy
with drugs that cause immune system activation was already
described in the 1970s (87). However, only in the past
10 years has this type of treatment started to be developed.
Currently, there is still a lack of information about the ideal
combination of ionizing radiation with immunotherapy, and
there are no recommended ‘‘off-protocol’’ approaches already
established for routine patient management.
The main objective of the current ongoing trials is to
evaluate the abscopal effect of the combination of ionizing
radiation with immunotherapy, mainly in patients with
advanced disease.
Different vaccines and immune checkpoint inhibitors are
combined with radiotherapy that is delivered to the primary
tumor or metastatic sites in oligometastatic disease. Among
these, vaccinia prostate-specific antigen (rV-PSA), Toll-like
receptor (TLR)-7 agonist, cytokine FLT3L ligand (CDX-301),
anti-programmed cell death-1 (PD-1), anti-programmed cell
death ligand-1 (PD-L1), and anti-cytotoxic T-lymphocyte
associated protein 4 (CTLA-4) antibodies, IL-2, recombined
human granulocyte-macrophage colony stimulating factor
(rhGM-CSF), and tyrosine kinase inhibitors (TKIs) have been
identified and tested (44,88-92).
The trials involve distinct tumor sites, in different stages of
the disease, most frequently in the metastatic setting. All are
phase 1 or 2, and radiotherapy is preferentially delivered with
SBRT.
Some of these ongoing trials from New York University
(NYU), the Earle A. Chiles Research Institute (EACRI), the
Providence Cancer Center (Providence Portland Medical
Center, Oregon) (PH&S IRB), Stanford University, the National
Institute of Health/National Cancer Institute (NIH/NCI) and
Thomas Jefferson University were already well described in a
recent review (93). Table 1 displays other ongoing clinical
trials registered at ‘‘clinicaltrials.gov’’ that are studying the
abscopal effect of ionizing radiation combined with immu-
notherapy. A glossary of the drugs used in these trials is
available in the Appendix.
Over time, patients enrolled in these trials are carefully
monitored regarding their immune function. We hope that
important data about the pro-immunogenic effects of the
combination of different immune modulators with radiation
in different disease settings will soon be available.
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’ FINAL REMARKS
Radiotherapy technology is progressively evolving to
more precise and safe treatments, with better normal tissue
sparing and the potential to deliver high ablative doses to the
tumor.
Molecular biology studies are allowing the development of
many anti-cancer agents with more specific targeted treat-
ments.
The effects of these treatments in the immune system and
the benefits of these effects are still under intensive research.
Paradoxical effects of stimulation or immunosuppression
are observed in different scenarios and may contribute to
the success or lack of success of the different treatment
approaches.
Interaction of novel radiation therapy technologies with the
newly developed targeted agents are promising strategies for
cancer treatment. Hypofractionated radiotherapy seems to be
more effective regarding immunotherapy. Nevertheless, better
drug–radiation combinations, timing, sequences, radiation
doses and fractionation have yet to be defined.
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’ APPENDIX
Glossary of the drugs associated with radiotherapy
in the clinical trials
(from NIH-NCI Drug Dictionary, available at: www.
cancer.gov/publications/dictionaries/cancer-drug)
Autologous dendritic cells
A population of a type of antigen-presenting cell (APC),
the dendritic cell (DC), harvested from a patient and grown
in vitro in the presence of tumor-associated antigens (TAAs)
derived from the patient’s tumor (a technique known as
‘pulsing’) and then injected back into the patient; autologous
DCs so manipulated may stimulate a specific cell-mediated
antitumoral cytotoxicity. DCs derived from a patient may
also be fused with the patient’s tumor cells in vitro to com-
bine sustained tumor antigen expression with the antigen-
presenting and immunostimulatory capacities of DCs; when
injected back into the patient, these autologous DC-tumor
cell hybrids (fusion cells) may stimulate an active anti-
tumoral immune response.
Imiquimod
Imiquimod is a synthetic imidazoquinoline and Toll-like
receptor (TLR)-7 agonist. TLRs are highly conserved pattern
recognition receptors that alert the host to invading patho-
gens, thereby activating an innate immune response directly
and an adaptive immune response, secondarily. TLR7 is
located on endosomal membranes of antigen-presenting cells,
including myeloid dendritic cells (mDCs) and plasmacytoid
dendritic cells (pDCs), monocytes, and macrophages. TLR7
activation induces the secretion of proinflammatory cytokines,
predominantly interferon (IFN)-a, interleukin (IL)-12, and
tumor necrosis factor-a, and enhances DC maturation and
antigen presentation. This immunostimmulatory ability can
be harnessed to promote antitumor immunity, either by
applying the TLR agonist locally onto cancers or administer-
ing it as an adjuvant for cancer vaccines. Therefore, TLR
agonists are included in the ranked National Cancer Institute
(NCI) list of immunotherapeutic agents with the highest
potential to cure cancer. Imiquimod is approved by the Food
and Drug Administration in a topical 5% formulation for
the treatment of external genital warts, superficial basal cell
carcinoma, and actinic keratosis. Topically applied, imiqui-
mod exerts profound immunomodulatory effects on the
tumor microenvironment, leading to immune-mediated clear-
ance of primary skin and mucosal malignancies.
Polylysine and carboxymethylcellulose (Poly-ICLC)
Poly-ICLC may stimulate the release of cytotoxic cyto-
kines and, by inducing interferon-gamma production, may
increase the tumoricidal activities of various immunohema-
topoietic cells.
Thymalfasin
Thymalfasin is a synthetic analogue of thymosin-alpha-1,
a 28-amino acid protein derived from the precursor protein
prothymosin-alpha. Exhibiting a variety of immunoregulat-
ing properties, thymosin-alpha-1 induces differentiation of
murine T-cell precursors and human thymocytes and the
terminal differentiation of functionally immature cord blood
lymphocytes and induces production of IL-2, high affinity
IL-2 receptors, and B-cell growth factors by peripheral blood
mononuclear cells. T-helper and cytotoxic/suppressor T-cell
populations are targets of thymosin activity. Thymosin-
alpha-1 has been shown to increase the efficiency of antigen
presentation by macrophages and to be an endogenous
modulator of alpha-thrombin activity.
Tirosine-kynase inhibitors (TKIs)
LY2157299 Monohydrate (galunisertib). Galunisertib
is an orally available, small molecule antagonist of the tyro-
sine kinase transforming growth factor-beta (TGF-b) receptor
type 1 (TGF-bR1), with potential antineoplastic activity. Upon
administration, galunisertib specifically targets and binds to
the kinase domain of TGF-bR1, thereby preventing the
activation of TGF-b-mediated signaling pathways. This may
inhibit the proliferation of TGF-b-overexpressing tumor cells.
Dysregulation of the TGF-b signaling pathway is seen in a
number of cancers and is associated with increased cancer cell
proliferation, migration, invasion and tumor progression.
Anti-CTLA-4
Ipilimumab (MDX CTLA-4). Ipilimumab is a recombi-
nant human immunoglobulin (Ig) G1 monoclonal antibody
directed against the human T-cell receptor cytotoxic
T-lymphocyte-associated antigen 4 (CTLA4), with immune
checkpoint inhibitory and antineoplastic activities. Ipilimu-
mab binds to CTLA4 expressed on T-cells and inhibits the
CTLA4-mediated downregulation of T-cell activation. This
leads to a cytotoxic T-lymphocyte (CTL)-mediated immune
response against cancer cells. CTLA4, an inhibitory receptor
and member of the immunoglobulin superfamily, plays a key
role in the downregulation of the immune system.
Anti-PD-1
Nivolumab. Nivolumab is a genetically engineered, fully
human immunoglobulin G4 (IgG4) monoclonal antibody
directed against the negative immunoregulatory human cell
surface receptor programmed death-1 (PD-1, PCD-1) with
immune checkpoint inhibitory and antineoplastic activities.
Nivolumab binds to and blocks the activation of PD-1, an Ig
superfamily transmembrane protein, by its ligands pro-
grammed cell death ligand 1 (PD-L1), which is overexpressed
on certain cancer cells, and programmed cell death ligand 2
(PD-L2), which is primarily expressed on APCs. This results in
the activation of T-cells and cell-mediated immune responses
against tumor cells or pathogens. Activated PD-1 negatively
regulates T-cell activation and plays a key role in tumor
evasion from host immunity.
Pembrolizumab. Pembrolizumab is a humanized mono-
clonal immunoglobulin (Ig) G4 antibody directed against
human cell surface receptor PD-1 (programmed death-1 or
programmed cell death-1) with potential immune checkpoint
inhibitory and antineoplastic activities. Upon administration,
pembrolizumab binds to PD-1, an inhibitory signaling receptor
expressed on the surface of activated T cells, and blocks the
binding to and activation of PD-1 by its ligands, which results
in the activation of T-cell-mediated immune responses against
tumor cells. The ligands for PD-1 include programmed cell
death ligand 1 (PD-L1), which is overexpressed on certain
cancer cells, and programmed cell death ligand 2 (PD-L2),
which is primarily expressed on APCs. Activated PD-1 nega-
tively regulates T-cell activation and plays a key role in tumor
evasion from host immunity.
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